National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 8 of 1999)

Overview

The National Health Act 1953, enacted by the Commonwealth Parliament, serves as the foundational legislative framework for the administration of health services in Australia, including the regulation of pharmaceuticals through the Pharmaceutical Benefits Scheme (PBS). The Act was introduced to address the need for a coordinated and equitable system for providing access to essential medicines, ensuring that Australians have access to affordable and necessary pharmaceutical treatments. One particular legislative instrument under this Act, F2007B01081, specifies a declaration made by the Assistant Secretary of the Pharmaceutical Benefits Branch, Department of Health and Aged Care, on behalf of the Minister for Health and Aged Care. This declaration, which came into effect on 1 August 1999, removes certain drugs and medicinal preparations from the scope of Part VII of the National Health Act 1953, thereby altering their eligibility under the PBS. The policy objective behind such amendments is to refine the list of covered pharmaceuticals, ensuring that resources are allocated efficiently and effectively to those medications that provide the greatest benefit to the community.

Scope and Application

The Pharmaceutical Benefits Declaration under subsection 85 (2AA) of the National Health Act 1953 pertains specifically to the cessation of certain drugs and medicinal preparations from being subject to Part VII of the Act. This legislation applies to the entity named in the Schedule, in this instance, Dichlorphenamide, effectively removing it from the list of substances eligible for pharmaceutical benefits under the Act. The geographic and jurisdictional reach of this Act is Commonwealth, as it is an instrument of the Australian government. This Declaration is applicable nationally, impacting all states and territories within Australia. There are no exclusions, exemptions, or thresholds specified in this particular legislative instrument. The application and scope of this Act may be further defined or extended through subordinate instruments, which could include regulations or guidelines issued by the relevant authorities under the authority of the Act.

Key Provisions

The National Health Act 1953, under subsection 85 (2AA), allows for the declaration of certain drugs and medicinal preparations to cease being subject to Part VII of the Act. This particular legislative instrument (PB 8 of 1999) made by Brett Anthony Lennon, Assistant Secretary, Pharmaceutical Benefits Branch, Department of Health and Aged Care, and Delegate of the Minister for Health and Aged Care, specifies that certain drugs will no longer fall under the Pharmaceutical Benefits Scheme (PBS) as of 1 August 1999. Specifically, the drug mentioned in the Schedule, Dichlorphenamide, is to cease being covered by the Act (Section 2). This legislative instrument imposes the requirement on the relevant parties that once the Declaration comes into operation, Dichlorphenamide will no longer be considered a drug for the purposes of the PBS. This means that any prescriptions, claims, or benefits associated with Dichlorphenamide under Part VII of the National Health Act 1953 will no longer apply from the specified date. The Act ensures that the changes are effective and communicated clearly to all stakeholders, including healthcare providers and patients. In terms of consequences, the Act does not specify any particular offences, penalties, or civil or criminal consequences for the breach of this declaration. However, non-compliance with the terms of the Act and this legislative instrument could lead to administrative actions, including fines or other penalties as outlined in the broader framework of the National Health Act 1953. The exact penalties would depend on the nature and severity of the breach, as well as the specific provisions of other related legislation.